Epigenetic regulation of the 1,25-dihydroxyvitamin D3 24-hydroxylase (CYP24A1) in colon cancer cells  by Höbaus, Julia et al.
E
(
J
D
A
R
R
A
K
C
H
M
E
5
T
1
D
h
s
c
a
h
T
m
D
M
V
i
(
0
hJournal of Steroid Biochemistry & Molecular Biology 136 (2013) 296– 299
Contents lists available at SciVerse ScienceDirect
Journal  of  Steroid  Biochemistry  and  Molecular  Biology
journa l ho me p age: www.elsev ier .com/ locate / j sbmb
pigenetic  regulation  of  the  1,25-dihydroxyvitamin  D3 24-hydroxylase
CYP24A1)  in  colon  cancer  cells
ulia  Höbaus,  Irfete  Sh.  Fetahu,  Maya  Khorchide,  Teresa  Manhardt,  Enikö  Kallay ∗
epartment of Pathophysiology and Allergy Research, Medical University of Vienna, Austria
a  r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 9 July 2012
eceived in revised form 31 July 2012
ccepted 9 August 2012
eywords:
YP24A1
istone deacetylase inhibitors
ethylation
pigenetics
-Aza-2′-deoxycytidine
richostatin A
a  b  s  t  r  a  c  t
Calcitriol  is  the  hormonally  active  form  of vitamin  D  and  has anti-proliferative  and  pro-apoptotic  effects.
Calcitriol  and  its  precursor  calcidiol  (25(OH)D3)  are  degraded  by  the  1,25-dihydroxyvitamin  D3 24-
hydroxylase  (CYP24A1).  This  enzyme  is  overexpressed  in  colorectal  tumors,  however,  the  mechanisms
of this  overexpression  remain  to be  elucidated.  CYP24A1  mRNA  level  differs  among  colorectal  cancer  cell
lines  and  range  from  almost  undetectable  to  high.  Since  DNA  methylation  and  histone  acetylation  regulate
CYP24A1  gene  expression  in  prostate  cancer  cell  lines,  we  investigated  whether  epigenetic  mechanisms
could  explain  the  differences  in  basal  expression  of  CYP24A1  in  colon  cancer  cells.  Methyltransferase
inhibitor  5-aza-2′-deoxycytidine  (DAC)  treatment  resulted  in  an  over  50-fold  induction  of  CYP24A1  mRNA
expression in Coga1A  and  HT-29  cells  but  in  no  response  in  Caco2/AQ  and  Coga13  cells.  This  ﬁnding  is
supported  by  a strong  increase  in CYP24A1  activity  after  DAC  treatment  in  Coga1A  (35%).  In addition,
calcitriol  and  DAC  had  synergistic  effects  on  CYP24A1  gene  transcription.  Interestingly,  the  CYP24A1
promoter  was  not  methylated  in  Coga1A  and  HT-29  (<5%),  while  in  Caco2/AQ  it was  62%  methylated.
This suggests  that  DNA  demethylation  must  activate  genes  upstream  of  CYP24A1  rather  than  act  on  the
gene itself.  However,  transcriptional  regulators  of  CYP24A1  such  as  vitamin  D  receptor  (VDR),  retinoid  X
receptor  (RXR),  speciﬁcity  protein  1  (SP1),  or mediator  complex  subunit  1  (MED1)  were  not  upregulated.
We  conclude  that  in  colon  cancer  cells,  CYP24A1  gene  expression  is  inducible  by  methyltransferase  and
some histone  deacetylase  inhibitors  in a  cell  line-dependent  manner.  This  effect  does  not  correlate  with
the methylation  state  of  the  promoter  and  therefore  must  affect  genes  upstream  of  CYP24A1.
This article  is  part  of  a  Special  Issue  ‘Vitamin  D  Workshop’.. Introduction
The most active vitamin D metabolite 1,25-dihydroxyvitamin
3 (calcitriol) is a pleiotropic secosteroid hormone that seems to
ave anti-tumorigenic effects in several cancer types [1,2]. High
erum levels of its precursor 25-hydroxyvitamin D3 (calcidiol)
orrelate with reduced risk of colorectal cancer [3]. The calcidiol
nd calcitriol degrading enzyme 1,25-dihydroxyvitamin D3 24-
ydroxylase (CYP24A1) is overexpressed in colorectal tumors [4].
he causes of this deregulation are poorly understood but would
ost likely reduce the anti-tumorigenic effects of calcitriol. In
Abbreviations: SP1, speciﬁcity protein 1; MED1, mediator complex subunit 1;
AC, 5-aza-2′-deoxycytidine; TSA, trichostatin A.
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prostate cancer cell lines, CYP24A1 expression was  shown to be
regulated by promoter DNA methylation and histone acetylation
[5]. In the present study we investigated the involvement of epi-
genetic mechanisms as the causes of different CYP24A1 expression
levels and sensitivity to calcitriol in colorectal cancer cell lines.
2. Materials and methods
2.1. Cell culture
At 30% conﬂuency Coga1A, Caco2/AQ, HT-29, and Coga13 cells
were treated with either 5-aza-2′-deoxycytidine (DAC) or tricho-
statin A (TSA) or a combination of both. Cells were treated with
DAC (1 M in PBS) every 24 h for 3 consecutive days followed by a
24 h treatment with TSA (100 nM in DMSO) after which cells were
harvested. For calcitriol treatment, 10 nM calcitriol was  added 5 h
Open access under CC BY-NC-ND license.before the end of the experiment. Controls were treated with 0.01%
EtOH and 0.01% DMSO. For long term effect of DAC, Caco2/AQ,
Coga1A and HT-29 cells were treated with 1 M DAC every 24 h
for 3 days and total RNA was  isolated 8 days after last treatment.
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.2. RNA isolation and reverse transcription (RT) and quantitative
T-PCR
RNA was extracted with Trizol (LifeTechnologies, Vienna,
ustria) and reverse transcribed with RevertAid H Minus Reverse
ranscriptase (Fermentas, St. Leon-Rot, Germany) using random
examer primers.
We  screened ﬁve reference genes for stable expression after TSA
nd DAC treatments and selected beta-2-microglobulin (B2M) as
he reference gene since it was not affected by the drugs. Quantita-
ive RT-PCR was performed in duplicates with POWER SYBR GREEN
astermix (LifeTechnologies) on a StepOnePlus Real Time PCR
ystem (LifeTechnologies). CT was calculated relative to the ref-
rence gene B2M and total human RNA (Clontech, Mountain View,
A, USA) was used as calibrator. Graphs were made using Graph-
ad Prism software v5. Primer sequences of CYP24A1 and VDR
ave been described before [6], RXRalpha (fwd: GGACATGCAGATG-
ACAAGAC, rev: CCTTGGAGTCAGGGTTAA-AGAG), MED1 (fwd:
GTCAAGTCATGGAGAAGAG, rev: CCAAACGATCAGTCATTGCT), SP1
fwd: TCAACTCTCCTCCATGCCAG, rev: TTTCTCCTTCCTCTCCACCT).
.3. Bisulﬁte sequencing of genomic DNA
Bisulﬁte genomic sequencing primers were designed using
ethyl Primer Express v1.0 (LifeTechnologies): region 1 (fwd:
TTTTAGTTTAGGTTGGGGGTATTT, rev: CCATATTCCTATACCCAAA-
ACCAT), region 2 (fwd: TTTTTGGGTATAGGAATATGGAGAG, rev:
CCAACAATAACCAACTAATAAAAC). DNA was phenol/chloroform
ig. 1. Treatments with the methyltransferase inhibitor, 5-aza-2′-deoxycytidine (DAC)
xpression and activity in a cell line dependent manner. (A) CYP24A1 mRNA expression
elative to the vehicle treated control of each run. Columns represent mean of 3 experime
ompared with vehicle treated control, asterisk above brackets compared with calcitriol
nal  DAC treatment. (C) HPLC detection of CYP24A1 metabolites in cell lines after DAC tr& Molecular Biology 136 (2013) 296– 299 297
extracted and bisulﬁte-converted with the EpiTect Bisulﬁte Kit
(Qiagen, Hilden, Germany). PCR ampliﬁcation was performed using
HotStarTaq DNA Polymerase (Qiagen) and gel-puriﬁed with Pure-
Link Quick Gel Extraction Kit (LifeTechnologies). Cloning was
performed with the Topo TA Cloning Kit for Subcloning with
chemically competent bacteria (LifeTechnologies). Miniprep and
DNA-Sequencing was performed by Microsynth AG (Balgach,
Switzerland). Sequencing results were analyzed with the BiQAn-
alyzer software (60).
2.4. High pressure liquid chromatography (HPLC)
HPLC was  performed as described before [7].
3. Results
3.1. Induction of CYP24A1 expression and activity by inhibition of
methyltransferases
To assess basal CYP24A1 mRNA expression and inducibility by
calcitriol, we treated the colon cancer cell lines Caco2/AQ, Coga1A,
Coga13, and HT-29 with 10 nM calcitriol for 5 h and assessed mRNA
expression. All cell lines showed low basal CYP24A1 expression
which was  highly inducible by calcitriol with the exception of
Coga13 cells where the high basal CYP24A1 levels could not be
further elevated by calcitriol (Fig. 1A). To evaluate whether differ-
ences in promoter DNA methylation and histone acetylation could
explain the differences in CYP24A1 gene expression among cell
 and the histone deacetylase inhibitor trichostatin A (TSA) alter CYP24A1 mRNA
 in cells treated with DAC and TSA followed by calcitriol. Each experiment was set
nts; bars indicate SEM. Asterisks above bars indicate statistical signiﬁcant changes
 treated control (*p < 0.05, **p < 0.001). (B) CYP24A1 mRNA expression 8 days after
eatment and control, enzymatic activity evaluated from areas under the curve.
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F DAC and TSA treatment. (A) Expression of vitamin D receptor (VDR), retinoid X receptor
(  DAC treatment in four colon cancer cell lines, columns represent mean of 3 experiments;
b g location of response elements and bisulﬁte sequencing regions.
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Table 1
Promoter methylation of CYP24A1 in colon cancer cell lines.
Cell line CYP24A1 mRNA expression DNA methylation (%)
Region 1 Region 2
Caco2/Aq 0.02 62 89
Coga1A 0.03 1 60
Coga13 32.75 3 60
HT-29 0.005 3 n.d.ig. 2. Transcription factors and co-activators of CYP24A1 are not upregulated by 
RXR),  speciﬁcity protein 1 (SP1), mediator complex subunit 1 (MED1) after TSA and
ars  indicate SEM. (B) Schematic overview of the CYP24A1 promoter region showin
ines, we treated cells with the DNA methyltransferase inhibitor 5-
za-2′-deoxycytidine (DAC) and the histone deacetylase inhibitor
richostatin A (TSA) in the presence and absence of calcitriol.
one of the investigated cell lines upregulated CYP24A1 expression
fter TSA treatment, however, the histone deacetylation inhibitor
odium butyrate but not suberoylanilide hydroxamic acid (SAHA)
ncreased CYP24A1 expression in HT-29 cells but not Caco2/AQ
data not shown). In Coga1A and HT-29 cells DAC resulted in a
trong increase of basal CYP24A1 transcription which was still
bserved 8 days after treatment was terminated (Fig. 1A and B).
he combination of DAC and calcitriol had a synergistic effect on
hese cells, while Coga13 and Caco2/AQ cells showed no response
o DAC. As a control, we assessed CYP24A1 activity in Coga1A and
oga13 cells after treatment with DAC. While activity increased
nly marginally in Coga13, we detected a 35% increase of CYP24A1
ctivity in Coga1A cells (Fig. 1C)..2. Promoter methylation of CYP24A1
We  performed bisulﬁte genomic sequencing of the promoter
egion 1 (−949 to +3) and region 2 (−18 to +609) of the CYP24A1gene locus (Fig. 2B). Region 1 is located upstream to the transcrip-
tion start site and showed less than 5% methylation in Coga1A,
Coga13, and HT-29 and 62% methylation in Caco2/AQ. Region 2 is
located after the transcription start site and showed high overall
methylation (Table 1). As a control, we bisulﬁte sequenced pro-
moter region 2 after DAC treatment and observed a 65% decrease
in methylation in Caco2/AQ cells and a 10% decrease in Coga1A
(Table 2).
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Table 2
Promoter methylation of CYP24A1 after 3 days of treatment with 1 M 5-Aza-2′-
deoxycytidine.
Cell line Increase in CYP24A1 mRNA
expression
DNA methylation (%)
Region 2
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15599–15610.Caco2/AQ 0.57-fold 31 (65% reduction)
Coga1A 54-fold 54 (10% reduction)
.3. Effect of DAC treatment on transcription factors and
o-activators regulating CYP24A1 expression
To assess whether the DAC treatment upregulated CYP24A1
ene transcription through an indirect mechanism, we determined
he expression of several upstream transcription factors and co-
ctivators of CYP24A1 which contain CpG islands close to their
ranscription start sites. Since DAC treatment and calcitriol had syn-
rgistic effects, we assessed the expression of vitamin D receptor
VDR) and retinoid X receptor (RXR), the main transcription factors
ediating CYP24A1 transcription. In addition, we  assessed expres-
ion of mediator complex subunit 1 (MED1) which is thought to
ct as a bridge between transcription factors and polymerase II [8]
nd speciﬁcity protein 1 (SP1) which plays a role in both basal and
itamin D induced transcription of CYP24A1. Surprisingly, none of
hese genes were up regulated after DAC treatment (Fig. 2A).
. Discussion
In this study, we showed that in colon cancer cell lines the
romoter methylation status of CYP24A1 does not correspond
o basal and vitamin D induced expression of CYP24A1. Further,
e observed a cell line speciﬁc strong up regulation of CYP24A1
xpression after treatment with the methyl transferase DAC which
howed synergistic effects in combination with calcitriol. How-
ver, this up regulation did not correlate with CYP24A1 promoter
ethylation status.
The mechanisms behind the over expression of CYP24A1 in
olorectal cancer are not clearly understood but may  include gene
mpliﬁcation and epigenetic modiﬁcations. Multiple transcription
actor binding sites are located upstream of the CYP24A1 tran-
cription start site, including two vitamin D response elements
nd SP1 binding sites. A large CpG island spans the CYP24A1 pro-
oter and therefore, DNA methylation of this region could lead to
ene silencing. In prostate cancer cell lines, the CYP24A1 promoter
ethylation state correlated with gene expression [5,9]. Treatment
ith demethylating agents increased mRNA expression only in
ell lines that showed promoter methylation before treatment. We
ypothesized that in colon cancer cell lines the differences in basal
nd calcitriol induced transcription of CYP24A1 could also be due
o differences of promoter methylation and acetylation status. It is
nteresting that in colon cancer cell lines the histone deacetylase
nhibitor TSA did not affect CYP24A1 expression while it affected
ene transcription in prostate cancer cell lines [5,9]. Interestingly,
atrium butyrate, another histone deacetylase inhibitor, ampliﬁed
asal CYP24A1 expression, again in a cell line-dependent manner.
Although inhibition of methyltransferases strongly induced
YP24A1 expression in two of the tested cell lines, this effect can-
ot be attributed to demethylation of CYP24A1 promoter, since a
[& Molecular Biology 136 (2013) 296– 299 299
65% reduction of methylation achieved less than 4-fold transcrip-
tional increase in Caco2/AQ, while a methylation decrease by 10%
was  accompanied by a 42-fold increase in Coga1A. Several distant
regulatory elements have been described in addition to the ones
proximal to the transcription start site, [10,11] however, these ele-
ments are not located within CpG islands and therefore it is unlikely
that DAC treatment would inﬂuence their activity. The synergis-
tic effect of DAC and calcitriol suggested that genes involved in
regulation of calcitriol-induced CYP24A1 transcription might be
possible candidates of genes that could be induced by DAC, how-
ever neither VDR and RXR, the classical mediators of calcitriol
signaling nor MED1 and SP1, both required for basal and calcitriol
induced CYP24A1 transcription, responded to DAC treatment. In
conclusion, the induction of CYP24A1 transcription after methyl-
transferase inhibitor treatment seems to be due to the altered
expression of unidentiﬁed regulators of CYP24A1 expression rather
than demethylation of the gene itself.
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